A Fatal Diagnosis

DIPG is a rare disease, diagnosed annually in only 1–2 cases per 1,000,000 inhabitants. Unfortunately, the average survival time for patients with this diagnosis is less than one year. This cruel prognosis has not improved in over 30 years. Furthermore, surgical removal of the tumor is not possible because it infiltrates the sensitive tissue of the brainstem, where centres controlling key vital functions are located.

Despite extensive research, available chemotherapy has not led to significant improvements in survival. Currently, the most common treatment is radiation (radiotherapy). However, this offers only temporary relief from symptoms, not a permanent solution.
 

We are helping to change this situation.

The Difficult Reality of DIPG

It mostly affects children aged 6–7. But it does not spare adults either.

Average survival time is between 9–11 months.

A total of 90% of children die within 2 years of diagnosis.

Less than 1% of patients achieve long-term survival. 

Hope for Improvement

Recent research results have significantly advanced our understanding of the molecular mechanisms behind this serious disease. These findings bring new hope for the future identification of effective treatment.

A promising shift is represented by preclinical studies of molecularly targeted substances, which have already advanced to late phases of clinical evaluation. In addition, immunotherapy, which specifically includes CAR T-cell therapy, oncolytic viruses, and vaccine therapy, appears to be a highly promising approach in the fight against the disease.

Our goal is to support new treatment options and patient care in the Czech Republic and to improve the situation for pediatric patients who currently depend on treatment abroad.

We value your privacy

This website uses cookies primarily for traffic analysis. Read more in our privacy policy.